Aliskiren-HCT approved for hypertension treatment

Bakris, George L.
March 2008
Hem/Onc Today;3/10/2008, Vol. 9 Issue 4, p52
This article reports on a direct renin inhibitor antihypertensive that was approved by the U.S. Food and Drug Administration for the treatment of hypertension. Two hypertension medications have been combined into a single pill called aliskiren-hydrochlorothiazide, which is designed to minimize the amount of medication taken by patients. Dizziness and diarrhea are considered as the most common side effects.


Related Articles

  • Late-stage hypertension drugs show promise. Belden, Heidi // Drug Topics;9/17/2007, Vol. 151 Issue 18, p46 

    The article discusses developments in antihypertensive agents in the U.S. Novartis' oral renin inhibitor aliskiren had been approved by the Food and Drug Administration (FDA) to treat hypertension (HTN) in March 2007. It blocks the action of renin at the top of the renin-angiotensin system...

  • New Type of BP Treatment Now Available.  // RN;Apr2007, Vol. 70 Issue 4, p61 

    The article reports on the approval of aliskiren, the first in a new class of drugs called direct renin inhibitors, as treatment for hypertension by the U.S. Food and Drug Administration (FDA). The effectiveness of the drug has been proven in more than 2,000 patients with mild-to-moderate...

  • NEWS.  // Clarendon Enterprise (TX);12/5/2013, Vol. 24 Issue 49, p5 

    The article offers brief information on the drug macitentan with the brand name Opsumit which has been approved by the U.S. Food and Drug Administration for the treatment of pulmonary arterial hypertension (PAH) in adults.

  • FDA advisory panel favors approval of riociguat. Swain, Erik // Cardiology Today;Sep2013, Vol. 16 Issue 9, p16 

    The article focuses on the recommendation given by the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food & Drug Administration (FDA), on August 2013, to approve the use of riociguat for treatment of patients with pulmonary arterial hypertension and patients with chronic...

  • New Triple Therapy for Hypertension Approved.  // Clarendon Enterprise (TX);2/ 3/2011, Vol. 22 Issue 8, p8 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved a new triple therapy medication called Amturnide, which can be used for the treatment of hypertension through the combination of a calcium channel blocker, a renin inhibitor, and a diuretic.

  • FDA O.K.'s Daiichi Sankyo's Benicar.  // Chain Drug Review;3/15/2010, Vol. 32 Issue 6, p84 

    The article reports on the approval of the drug Benicar as hypertension treatment from Daiichi Sankyo Inc. by the U.S. Food and Drugs Administration.

  • DRUG APPROVED TO TREAT PULMONARY HYPERTENSION.  // Medical Economics;12/25/2103, Vol. 90 Issue 24, p19 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved riociguat (Adempas) tablets for treating chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) in adults and the drug can overcome nitric oxide (NO) dependence.

  • FDA Drug Approvals.  // Geriatrics;Mar2005, Vol. 60 Issue 3, p22 

    The article reports on drugs which are approved by the U.S. Food and Drug Administration. Eszopiclone is a non-benzodiazepine hypnotic for treatment of insomnia. Eszopiclone interacts with gammaamino butyric acid receptors. Eszopiclone's effect on sleep onset may be reduced if taken with or...

  • FDA Approves Cleviprex for Acute Hypertension. Hollingsworth, Catherine // BioWorld Today;8/5/2008, Vol. 19 Issue 151, p1 

    The article reports on the approval granted by the U.S. Food and Drug Administration (FDA) to Parsippany, New Jersey-based The Medicines Co. (MDCO) for its intravenous drug for high blood pressure, Cleviprex. The company plans to launch the antihypertensive for use in the critical care setting,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics